InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| REVENUE | — | — | — | — | $0 |
| Research and development expenses | $456K+89.8% | $240K+191.2% | $83K | — | $226K |
| Advertising and marketing expenses | $4K-94.7% | $84K | $0 | — | — |
| Professional fees | $320K-70.1% | $1.1M+59.4% | $672K+188.3% | $233K+160.1% | $90K |
| Compensation and related benefits | $5.5M+317.4% | $1.3M+70.7% | $772K | — | — |
| Other general and administrative expenses | $131K+87.7% | $70K+179.6% | -$88K-373.2% | $32K-81.2% | $171K |
| Total Operating Expenses | $6.4M+130.3% | $2.8M+93.4% | $1.4M-64.6% | $4.1M+31.0% | $3.1M |
| LOSS FROM OPERATIONS | -$6.4M-130.3% | -$2.8M-93.4% | -$1.4M+64.6% | -$4.1M-31.0% | -$3.1M |
| Interest expense | -$60K-238.1% | -$18K+59.6% | -$44K+14.3% | -$51K+50.3% | -$103K |
| Net gain on settlement of accounts payable | $14K | — | — | — | — |
| Gain on extinguishment of notes payable | $867K+14781.6% | $6K+105.5% | -$105K-2000.0% | -$5K | — |
| Penalties | -$90K | — | -$120K | — | -$120K |
| Other expense | -$44 | — | — | — | — |
| Total Other Expense | $821K+905.4% | -$102K+62.1% | -$269K-52.5% | -$176K | — |
| LOSS BEFORE INCOME TAXES | -$5.6M-93.7% | -$2.9M-69.0% | -$1.7M | — | — |
| NET LOSS | -$5.6M-93.7% | -$2.9M-69.0% | -$1.7M+59.7% | -$4.2M | — |
| Earnings Per Share, Diluted | -$0.22-46.7% | -$0.15-66.7% | -$0.09+30.8% | -$0.13 | — |
| Weighted Average Number of Shares Outstanding, Diluted | $25.7M+29.3% | $19.9M+1.7% | $19.5M-39.7% | $32.4M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Genvor Appoints Donald Kalkofen as Chief Financial Officer
Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline
Genvor to Present at Centri Capital Conference on April 14
Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026